External-beam radiation therapy (EBRT) treats prostate cancer by directing high-energy radiation from a machine outside the body toward a precisely planned target inside the pelvis. Modern prostate EBRT usually combines intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT). The treatment can be delivered over several weeks or, in selected patients, compressed into shorter hypofractionated or stereotactic schedules while maintaining comparable cancer control.
EBRT is a standard curative treatment for localized and selected locally advanced prostate cancer. The radiation oncologist first maps the prostate, tumor, seminal vesicles, pelvic nodes when relevant, and nearby normal organs on planning imaging. A computer then shapes many beam angles or arcs so the prescribed dose overlaps in the target while limiting exposure to the bladder, rectum, urethra, bowel and other organs. Moderate hypofractionation such as 60 Gy in 20 fractions is now a standard schedule, and five-fraction SBRT is an evidence-based option for selected low- and intermediate-risk patients.
01How Is External-Beam Radiation Planned Before the First Treatment?
EBRT begins with simulation rather than radiation delivery
Before treatment, the patient undergoes a planning session called CT simulation.
The purpose is to reproduce the position that will be used during every radiation fraction and to create a three-dimensional anatomical dataset for treatment planning.
The simulation can include:
- thin-slice pelvic CT;
- MRI fusion for prostate and tumor definition;
- immobilization and body-positioning devices;
- bladder-filling instructions;
- rectal-emptying instructions where used;
- fiducial markers in selected programs;
- and a rectal spacer in selected patients.
Why is the bladder often kept comfortably full?
A reproducibly filled bladder can move part of the small bowel away from pelvic radiation fields and create a more consistent relationship between the bladder and prostate.
The goal is not maximal bladder distension. It is repeatability.
Why does rectal preparation matter?
The prostate sits immediately in front of the rectum.
Gas or stool can push the prostate forward or alter its shape and position from one treatment day to another.
Some centres therefore use dietary instructions, bowel routines or other preparation to reduce extreme variation.
What is contoured on the planning scan?
The radiation oncologist outlines several structures.
These can include:
- gross tumor volume (GTV) when a dominant tumor is visible on MRI;
- clinical target volume (CTV), typically the prostate plus selected adjacent tissue depending on disease risk;
- planning target volume (PTV), which adds a margin for motion and setup uncertainty;
- bladder;
- rectum;
- urethra in selected protocols;
- bowel;
- femoral heads;
- penile bulb and sexual structures where relevant;
- and pelvic lymph-node volumes when nodal treatment is planned.
Why does the PTV extend beyond the visible prostate?
A radiation plan cannot assume the prostate stays perfectly stationary.
The additional planning margin accounts for:
- small daily setup differences;
- internal prostate motion;
- bladder and rectal filling changes;
- and uncertainty in target localization.
Better image guidance can allow tighter margins, which can reduce normal-tissue exposure.
What is MRI fusion?
MRI is often better than CT at showing the prostate boundary, seminal vesicles and dominant intraprostatic lesions.
The MRI can be registered to the planning CT so the radiation team uses the CT for dose calculation and the MRI for improved soft-tissue definition.
What is a rectal spacer?
A rectal spacer creates temporary separation between the prostate and anterior rectal wall.
Increasing that distance can reduce rectal radiation dose in appropriately selected patients.
The spacer is not required for every EBRT plan, and placement itself has procedural risks. Its value depends on anatomy, dose schedule and the quality of the baseline plan.
The quality of an EBRT course is partly determined before treatment starts. Accurate contouring, realistic organ-at-risk constraints and reproducible bladder/rectal preparation can matter as much as the nominal prescription written on the treatment chart.
02How Are IMRT, VMAT and Image-Guided Radiation Delivered?
IMRT changes beam intensity across the treatment field
Intensity-modulated radiation therapy uses computer-controlled multi-leaf collimators to shape both:
- the outline of each radiation beam;
- and the intensity within different parts of that beam.
This allows the plan to wrap a high-dose region around the prostate while lowering dose to the rectum and bladder.
Current EAU guidance recognizes IMRT or VMAT with IGRT as the standard EBRT approach for prostate cancer.
What is VMAT?
Volumetric-modulated arc therapy is an IMRT delivery method in which the linear accelerator rotates around the patient.
During the arc:
- the beam shape changes;
- dose rate changes;
- and gantry speed can change.
VMAT often delivers a treatment efficiently while maintaining highly conformal dose.
What is a linear accelerator?
A linear accelerator—or LINAC—is the machine that produces the high-energy x-rays used for most prostate EBRT.
The patient lies on a treatment couch while the gantry rotates around the body. The machine does not touch the prostate.
What does image guidance do?
Image guidance verifies the prostate or treatment target immediately before or during radiation delivery.
Common methods include:
- cone-beam CT;
- kilovoltage x-rays with fiducial markers;
- surface-guidance systems;
- MRI-guided radiotherapy;
- and other onboard imaging platforms.
If the prostate is displaced beyond the acceptable tolerance, the treatment couch or patient setup can be corrected before the beam is delivered.
What is intrafraction motion?
The prostate can move not only between treatment days but also during a fraction.
Longer high-dose fractions—such as SBRT—make motion management especially important.
Some systems therefore use:
- continuous fiducial tracking;
- repeated imaging;
- MRI tracking;
- or treatment interruption if the target leaves a predefined boundary.
Does treatment hurt?
The radiation beam itself is not felt.
Patients usually do not feel heat, burning or energy entering the prostate during a standard fraction.
Treatment discomfort more often comes from:
- holding a comfortably full bladder;
- remaining still on the treatment couch;
- or urinary/bowel inflammation that accumulates over the treatment course.
IMRT/VMAT tells the machine how to shape dose; IGRT tells the team where the prostate is today. High-quality EBRT requires both functions.
03How Many EBRT Treatments Are Needed?
Fractionation means dividing the total dose into separate treatments
A single radiation treatment is called a fraction.
The total treatment dose is divided across fractions because normal tissue and tumor cells respond differently to both:
- the total radiation dose;
- and the size of each individual fraction.
What is conventional fractionation?
Conventional prostate EBRT historically used approximately 1.8–2.0 Gy per treatment over many weeks.
Examples include 76–78 Gy delivered over roughly 38–39 fractions.
This remains a valid approach but is no longer the only standard schedule.
What is moderate hypofractionation?
Moderate hypofractionation uses larger doses per fraction and therefore fewer treatment visits.
Current EAU guidance strongly supports schedules including:
- 60 Gy in 20 fractions over about four weeks;
- 70 Gy in 28 fractions over about six weeks.
The CHHiP randomized trial included 3,216 men and showed that 60 Gy in 20 fractions was non-inferior to 74 Gy in 37 fractions for biochemical or clinical control. At five years, failure-free rates were 90.6% with 60 Gy/20 fractions and 88.3% with 74 Gy/37 fractions.
Does a shorter 20-fraction course mean weaker treatment?
No.
The total physical dose is lower because the dose per fraction is higher. The biological effect—not the raw total Gy number—is what matters.
This is why 60 Gy in 20 fractions can be oncologically equivalent to a longer conventional course in appropriate patients.
What is ultra-hypofractionation or SBRT?
Stereotactic body radiation therapy gives a much larger dose per fraction over very few sessions.
Common prostate protocols use approximately five fractions.
EAU guidance includes five-fraction SBRT for selected favorable intermediate-risk patients with attention to urinary function.
How strong is the evidence for five-fraction SBRT?
PACE-B is a large randomized phase III trial of localized low- and intermediate-risk prostate cancer.
At a median 74 months of follow-up:
- five-year freedom from biochemical or clinical failure was 95.8% with SBRT;
- versus 94.6% with control radiotherapy;
- meeting the trial’s non-inferiority criterion.
However, late grade 2 or higher urinary toxicity was higher with SBRT:
- 26.9% after SBRT;
- versus 18.3% after control radiotherapy.
Late grade 2 or higher gastrointestinal toxicity was similar: 10.7% versus 10.2%.
Does that mean SBRT is unsafe?
No.
The PACE-B result shows that five-fraction prostate SBRT can achieve excellent cancer control, but the urinary-toxicity profile should be part of treatment selection and consent.
Baseline urinary symptoms, prostate size, dose constraints, motion management and treatment technique all matter.
Why are alternate-day schedules sometimes used for SBRT?
Some protocols separate large fractions by a day or more to allow normal tissue recovery.
EAU guidance describes ultra-hypofractionated schedules such as 36.25 Gy in five fractions or 42.7 Gy in seven fractions delivered on alternate days in selected favorable intermediate-risk patients.
Schedule convenience should not be separated from toxicity. Five-fraction SBRT can provide excellent control, but PACE-B showed more late grade ≥2 urinary toxicity than the longer control schedules. A shorter course is therefore a treatment choice—not simply a scheduling upgrade.
04How Do Risk Group, ADT, Pelvic Nodes and MRI Focal Boosting Change EBRT?
The target volume is not identical for every prostate cancer
The simplest EBRT plan treats the prostate.
As risk increases, the treatment volume can expand to include:
- part or all of the seminal vesicles;
- pelvic lymph nodes in selected higher-risk patients;
- and a higher-dose region inside an MRI-visible dominant tumor.
When is ADT omitted?
For low-risk and many favorable intermediate-risk cancers, definitive EBRT can be used without routine ADT.
This avoids unnecessary hormonal toxicity when the recurrence risk does not justify combined treatment.
When is short-course ADT added?
Unfavorable intermediate-risk disease commonly receives EBRT with approximately 4–6 months of ADT.
Current EAU guidance specifically combines 76–78 Gy conventional EBRT or moderate hypofractionation with short-term ADT in this setting.
When is long-course ADT used?
High-risk localized prostate cancer is generally treated with EBRT plus long-course ADT.
EAU guidance recommends approximately 2–3 years of ADT with definitive EBRT for high-risk disease.
When are pelvic lymph nodes treated?
Pelvic nodal irradiation is considered when the predicted probability of microscopic nodal disease is high enough to justify expanding the treatment field.
It is not routinely required for ordinary low-risk disease.
The trade-off is:
- potential treatment of occult nodal cancer;
- versus increased bowel, bladder and marrow exposure from the larger field.
What is MRI-guided focal boosting?
A focal boost delivers an extra radiation dose to a dominant intraprostatic tumor seen on MRI while the rest of the prostate receives the standard prescription.
Current EAU guidance supports focal boosting of an MRI-defined dominant lesion when organ-at-risk constraints can still be respected.
How strong is the focal-boost evidence?
The randomized FLAME trial included 571 men with intermediate- and high-risk localized prostate cancer.
At the original five-year analysis, biochemical disease-free survival was:
- 92% with a focal boost;
- versus 85% with standard whole-prostate EBRT.
Ten-year follow-up published in 2025 showed the advantage remained:
- 86% biochemical disease-free survival with focal boost;
- versus 71% without focal boost.
The trial did not demonstrate an overall-survival difference, but the biochemical-control benefit persisted long term.
Does every MRI lesion need focal boost?
No.
The boost should only be used when:
- the lesion can be defined reliably;
- the treatment technique can deliver the additional dose accurately;
- rectal, bladder and urethral constraints remain acceptable;
- and the strategy fits the patient’s risk group and treatment protocol.
What role does EBRT have after prostatectomy?
EBRT can also be used as salvage radiation after prostatectomy when PSA persists or rises.
That is a different clinical situation from primary prostate EBRT because the prostate has already been removed and the target becomes the prostate bed ± pelvic nodes.
This article focuses on definitive EBRT for an intact prostate.
| Risk / setting | Typical EBRT direction | ADT | Possible intensification |
|---|---|---|---|
| Low risk | Prostate-only modern EBRT if treatment is chosen. | Usually none. | Often no need; active surveillance should be considered first. |
| Favorable intermediate | Moderate HFX or selected SBRT. | Usually none. | MRI-guided focal boost in suitable protocols. |
| Unfavorable intermediate | IMRT/VMAT + IGRT; moderate HFX common. | About 4–6 months. | Brachytherapy boost or focal boost in selected patients. |
| High risk | Prostate + seminal-vesicle treatment; nodal field considered by risk. | Long course, commonly about 2–3 years in EAU framework. | Brachytherapy boost, pelvic nodes, selected systemic intensification. |
| Selected locally advanced / node-positive M0 | Prostate ± pelvis as part of multimodal therapy. | Long-term. | Selected systemic intensification according to current guideline criteria. |
EBRT planning intensifies in layers. Higher-risk disease can change the target, the dose distribution, the use of ADT and whether nodal or focal-boost treatment is appropriate. “Radiation therapy” should therefore never be interpreted as one identical prescription across all risk groups.
05What Does EBRT Feel Like, What Side Effects Occur and How Is Cancer Control Followed?
Most patients do not feel the radiation beam
A treatment visit usually includes:
- checking bladder and rectal preparation;
- positioning on the treatment couch;
- acquiring image guidance;
- correcting the setup if needed;
- and delivering the radiation beams or arcs.
The radiation delivery itself is painless.
When do urinary symptoms usually appear?
Urinary irritation often develops gradually during the treatment course.
Possible symptoms include:
- frequency;
- urgency;
- nocturia;
- burning;
- and a weaker stream.
These symptoms often improve after radiation ends, although a minority of patients develop persistent or late urinary effects.
What bowel symptoms can occur?
Rectal exposure can produce:
- increased bowel frequency;
- urgency;
- looser stools;
- rectal discomfort;
- or temporary bleeding.
Modern IMRT reduces high-dose exposure to the rectum compared with older 3D conformal techniques. EAU cites randomized evidence showing lower grade ≥2 urinary and gastrointestinal toxicity with IMRT without compromising biochemical control.
Does EBRT cause fatigue?
Yes, fatigue can build during multiweek treatment.
Fatigue can be amplified if ADT is given at the same time.
How does EBRT affect erections?
Erectile function can decline gradually after prostate radiation.
Risk depends on:
- baseline erectile function;
- age;
- vascular health;
- radiation dose to erectile structures;
- and whether ADT is added.
The pattern differs from prostatectomy, where erectile decline can be abrupt immediately after surgery.
What do five-year patient-reported outcomes show after prostate SBRT?
A 2026 PACE-B patient-reported-outcomes analysis provides a useful longer-term view of function after five-fraction SBRT compared with conventionally or moderately hypofractionated radiotherapy.
At five years:
- pad-free urinary continence: 91% after SBRT versus 90% after control radiotherapy;
- moderate or big urinary-leakage problems: 6% versus 4%;
- erections adequate for intercourse: 17% versus 20%;
- moderate or big bowel problems: 5% in both groups.
These patient-reported figures complement the physician-scored PACE-B toxicity results. They show that many men remain pad-free five years after either radiation schedule, while sexual function declines over time in both groups and clinically important bowel problems remain uncommon.
What are the important late EBRT complications?
Potential late effects include:
- chronic urinary urgency or bleeding;
- urethral stricture;
- radiation proctitis or rectal bleeding;
- gradual erectile dysfunction;
- and a small long-term increase in secondary bladder or gastrointestinal malignancies.
How is PSA interpreted after EBRT?
The prostate remains in the body, so PSA does not need to become undetectable.
Instead:
- PSA generally falls gradually;
- the lowest value is called the PSA nadir;
- a temporary PSA bounce can occur;
- and the classic Phoenix biochemical-recurrence definition is nadir + 2 ng/mL.
The broader radiation follow-up framework is covered in Radiation Therapy for Prostate Cancer.
How successful is modern EBRT?
Outcomes depend on risk group and whether treatment is appropriately intensified.
The evidence base includes large randomized trials showing:
- non-inferior cancer control with 60 Gy/20 fractions compared with longer conventional schedules in CHHiP;
- non-inferior five-year biochemical/clinical control with five-fraction SBRT in PACE-B for low/intermediate-risk disease;
- and improved long-term biochemical disease-free survival when an MRI-defined dominant tumor is focally boosted in selected intermediate/high-risk patients in FLAME.
Does EBRT have the same survival as surgery?
There is no universal answer independent of risk group, age and treatment era.
For many localized cancers, both surgery and modern radiation are accepted curative-intent options.
The decision is often driven as much by:
- urinary baseline;
- bowel health;
- sexual priorities;
- comorbidity;
- need for ADT;
- treatment logistics;
- and preference for surgery versus organ-preserving treatment;
as by cancer control alone.
Severe urinary retention, fever, heavy bleeding, rapidly worsening pelvic pain or major systemic deterioration should not be assumed to be routine EBRT toxicity. Those symptoms need clinical assessment.
→EBRT Technique and Schedule Comparison
| Approach | Typical concept | Main advantage | Main limitation / caution |
|---|---|---|---|
| Conventional IMRT/VMAT | Approximately 1.8–2.0 Gy per fraction over many weeks. | Long-established evidence base. | Highest visit burden. |
| Moderate hypofractionation | Examples: 60 Gy/20 fractions or 70 Gy/28 fractions. | Strong randomized evidence, fewer visits, standard-of-care option. | Still requires several weeks of daily treatment. |
| SBRT / ultra-HFX | Very large fractions, commonly about five treatments in selected patients. | Very low visit burden with excellent control in appropriate risk groups. | Requires strict image guidance and has a distinct urinary-toxicity profile. |
| VMAT | Modulated dose delivered during one or more rotating arcs. | Efficient conformal delivery. | Quality still depends on planning, contouring and IGRT. |
| MRI focal boost | Additional dose to dominant MRI-visible tumor within whole-prostate EBRT. | Improved biochemical control in FLAME. | Requires reliable lesion definition and safe organ-at-risk constraints. |
| Pelvic-node EBRT | Larger field includes regional pelvic nodal volumes. | Can treat occult nodal disease in selected high-risk patients. | Larger volume increases normal-tissue exposure; not routine for low-risk disease. |
Key Points
- EBRT treats prostate cancer using radiation from a machine outside the body.
- Modern prostate EBRT generally combines IMRT or VMAT with image guidance.
- CT simulation defines the geometry used for the entire treatment course.
- MRI fusion can improve prostate and dominant-tumor definition.
- Bladder and rectal preparation are used to make pelvic anatomy more reproducible.
- The planning target volume includes a margin for motion and setup uncertainty.
- Daily IGRT is essential because prostate position changes with bladder and rectal filling.
- VMAT is an arc-based method of delivering intensity-modulated radiation.
- The radiation beam itself is not felt during treatment.
- Moderate hypofractionation such as 60 Gy in 20 fractions is a standard evidence-based schedule.
- CHHiP showed 60 Gy/20 fractions was non-inferior to 74 Gy/37 fractions for biochemical/clinical control.
- Five-fraction SBRT is an evidence-based option for selected low/intermediate-risk disease.
- PACE-B showed 95.8% five-year freedom from biochemical/clinical failure with SBRT versus 94.6% with control radiotherapy.
- PACE-B also found more late grade ≥2 urinary toxicity with SBRT, so convenience should be balanced against toxicity.
- Unfavorable intermediate-risk disease commonly combines EBRT with about 4–6 months of ADT.
- High-risk disease generally combines EBRT with long-course ADT.
- Pelvic lymph nodes are treated selectively rather than routinely in every patient.
- MRI-defined focal boosting can improve biochemical control in selected intermediate/high-risk patients.
- At 10 years, FLAME reported 86% biochemical disease-free survival with focal boost versus 71% with standard EBRT.
- After EBRT, PSA declines gradually because the prostate remains in place.
Clinical bottom line: external-beam radiation therapy is a highly planned, image-guided treatment rather than a simple beam aimed at the prostate. The process begins with CT simulation and target contouring, uses IMRT or VMAT to shape dose, and relies on daily image guidance because the prostate moves. Moderate hypofractionation—particularly 60 Gy in 20 fractions—has a strong randomized evidence base and is now standard practice. Five-fraction SBRT can produce similarly excellent cancer control in selected low- and intermediate-risk patients, but the urinary-toxicity profile must be considered. As cancer risk rises, EBRT can expand from prostate-only treatment toward seminal-vesicle or pelvic-node coverage and can be combined with short- or long-course ADT. MRI-guided focal boosting can further intensify dose to the dominant tumor in selected patients. The quality of EBRT therefore depends on patient selection, planning accuracy, image guidance, fractionation choice, normal-tissue constraints and appropriate systemic treatment—not simply the machine used.
Medical disclaimer: This article provides general medical education about external-beam radiation therapy for prostate cancer. The target volume, dose, fractionation schedule, image-guidance method, use of ADT, pelvic-node treatment, rectal spacer, fiducial markers and focal boosting depend on cancer stage, Grade Group, PSA, imaging, urinary and bowel function, anatomy, comorbidity and local expertise. Individual treatment should be planned with a radiation oncologist and multidisciplinary prostate-cancer team.
For the complete radiation overview, return to Radiation Therapy for Prostate Cancer. For the overall disease-management pathway, review Prostate Cancer Treatment. The previous guide covers Robotic Prostatectomy. The next modality guide is Brachytherapy for Prostate Cancer. Long-term urinary, bowel, sexual and PSA follow-up is covered in Prostate Cancer Survivorship.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: IMRT/VMAT + IGRT, moderate and ultra-hypofractionation, ADT by risk group, focal boosting and modern EBRT recommendations.
- AUA/ASTRO — Clinically Localized Prostate Cancer Guideline: moderate and ultra-hypofractionated EBRT, radiation selection by risk group and combined therapy.
- ASTRO/ASCO/AUA — Hypofractionated Radiation Therapy for Localized Prostate Cancer: dose-fractionation, image guidance and patient-selection principles.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: EBRT indications, radiation evidence and stage-based context.
- CHHiP phase III trial — 60 Gy/20 fractions versus conventional EBRT; non-inferior biochemical/clinical control and comparable long-term toxicity.
- PACE-B phase III trial — five-fraction SBRT versus conventional/moderately hypofractionated control radiotherapy, including five-year cancer control and urinary/gastrointestinal toxicity.
- PACE-B 2026 patient-reported outcomes — five-year urinary continence, sexual-function and bowel-function outcomes after SBRT versus control radiotherapy.
- FLAME randomized phase III trial, 10-year follow-up — sustained biochemical disease-free survival benefit from MRI-defined focal boosting during prostate EBRT.
